A Kennedy Krieger Institute researcher is playing a role in a major international effort that has yielded a promising first-ever drug treatment for cerebral adrenoleukodystrophy (cALD)—a rare, often fatal genetic brain disease that impacts boys between ages 3 and 12.
This article was originally published on MedicalXpress.com